🏛️ Verified NIH Record • Updated 2026-03-02
Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC) (NCT05953337)
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC)
🔵 Active, Not Recruiting Observational / Diagnostic ⚙️ Medical Device Protocol Sponsor: ABK Biomedical
🩺 Plain-English Summary (8th-Grade Level)
This is a prospective, multi-center, open-label study to evaluate the effectiveness and safety of Eye90 microspheres® in the treatment of subjects with unresectable Hepatocellular Carcinoma (HCC). Eye90 microspheres is a medical device containing yttrium-90 (Y-90), a radioactive material, and provides local radiation brachytherapy for the treatment of liver tumors.
Who can join: Review the eligibility criteria below.
Location: The University of Arizona Cancer Center — Tucson, Arizona
Age range: 18 Years to 99 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (22 Sites)
- The University of Arizona Cancer Center — Tucson, Arizona
- University of California - Irvine — Orange, California
- AdventHealth Radiation Oncology at Altamonte Springs — Altamonte Springs, Florida
- Miami Cardiac and Vascular Institute at Baptist Hospital Miami — Miami, Florida
- Emory University Hospital Midtown — Atlanta, Georgia
- Piedmont Hospital — Atlanta, Georgia
- Northwestern University Memorial Hospital — Chicago, Illinois
- University of Illinois Hospital and Health Sciences System — Chicago, Illinois
- University of Iowa Health Care — Iowa City, Iowa
- University of Louisville — Louisville, Kentucky
- Ochsner Clinic Foundation — New Orleans, Louisiana
- Beth Israel Deaconess — Boston, Massachusetts
- University of Missouri - Ellis Fischel Cancer Center — Columbia, Missouri
- SSM Health Saint Louis University — St Louis, Missouri
- Weill Cornell Medicine-New York Presbyterian Hospital — New York, New York
- Charlotte Radiology — Charlotte, North Carolina
- Hospital of the University of Pennsylvania — Philadelphia, Pennsylvania
- HCA Healthcare Research Institute (Sarah Cannon) — Nashville, Tennessee
- University of Utah — Salt Lake City, Utah
- Inland Imaging — Spokane, Washington
- Froedtert Hospital/Medical College of Wisconsin — Milwaukee, Wisconsin
- Vancouver Coastal Health Research Institution (VCHRI) — Vancouver, British Columbia
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Hepatocellular Carcinoma
- TACE With or Without SBRT as Bridging Therapy for Pre-transplant HCC Patients — Maywood, Illinois
- Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab — San Diego, California
- Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC) — Baltimore, Maryland
- TheraSphere With Durvalumab and Tremelimumab for HCC — San Diego, California
- Blood Salvage in Orthotopic Liver Transplantation With HCC — Toronto, Ontario
- Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC) — Prescott Valley, Arizona
Explore by condition: All Hepatocellular Carcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.